Covered recipient · General Payments record
GIL YOSIPOVITCH
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$178,484.60
125 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $125,601.88 | 33 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,315.00 | 16 |
| Travel and Lodging | $13,824.91 | 26 |
| Food and Beverage | $3,723.50 | 49 |
| Education | $19.31 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $46,974.26 | 32 |
| GENZYME CORPORATION | $33,295.05 | 20 |
| Galderma Laboratories, L.P. | $31,049.57 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18,900.62 | 12 |
| Eli Lilly and Company | $13,085.95 | 7 |
| LEO Pharma Inc. | $8,660.47 | 7 |
| GlaxoSmithKline, LLC. | $7,200.00 | 1 |
| SANOFI US SERVICES INC. | $4,551.54 | 4 |
| Merck Sharp & Dohme LLC | $3,575.00 | 1 |
| Amgen Inc. | $3,200.00 | 1 |
| Arcutis Biotherapeutics, Inc. | $2,850.00 | 1 |
| Incyte Corporation | $1,630.00 | 1 |
| ABBVIE INC. | $1,257.29 | 4 |
| Blueprint Medicines Corporation | $800.00 | 1 |
| Boehringer Ingelheim International GmbH | $750.00 | 1 |
| Regeneron Pharmaceuticals, Inc. | $377.73 | 4 |
| Regeneron Healthcare Solutions, Inc. | $243.28 | 2 |
| Lilly USA, LLC | $83.84 | 1 |
Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GIL YOSIPOVITCH
NPI 1679558027 · CMS profile ID 30973
Allopathic & Osteopathic Physicians / Dermatology
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679558027?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GIL YOSIPOVITCH, NPI 1679558027, CMS profile ID 30973. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679558027?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). GIL YOSIPOVITCH, NPI 1679558027, CMS profile ID 30973. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679558027?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- GIL YOSIPOVITCH, NPI 1679558027, CMS profile ID 30973, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1679558027?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
125 matching records · $178,484.60 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–125 of 125.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $7,200.00 | 03/04/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190915754 | CMS |
| GENZYME CORPORATION | $2,865.00 | 02/28/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233375418 | CMS |
| Eli Lilly and Company | $900.00 | 02/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186622494 | CMS |
| Galderma Laboratories, L.P. | $65.90 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719572 | CMS |
| Galderma Laboratories, L.P. | $53.30 | 02/18/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719574 | CMS |
| Galderma Laboratories, L.P. | $13,050.00 | 02/13/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719570 | CMS |
| Eli Lilly and Company | $450.00 | 02/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186618976 | CMS |
| Regeneron Pharmaceuticals, Inc. | $146.82 | 02/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213245051 | CMS |
| LEO Pharma Inc. | $3,620.00 | 02/04/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252044412 | CMS |
| Galderma Laboratories, L.P. | $19.95 | 02/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719558 | CMS |
| Galderma Laboratories, L.P. | $35.00 | 02/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719560 | CMS |
| Galderma Laboratories, L.P. | $18.25 | 02/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719562 | CMS |
| Galderma Laboratories, L.P. | $482.69 | 02/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719564 | CMS |
| Galderma Laboratories, L.P. | $216.64 | 02/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719566 | CMS |
| Galderma Laboratories, L.P. | $404.07 | 02/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719568 | CMS |
| Galderma Laboratories, L.P. | $1,800.00 | 01/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719556 | CMS |
| Regeneron Pharmaceuticals, Inc. | $74.88 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213245049 | CMS |
| ABBVIE INC. | $56.37 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204827536 | CMS |
| Eli Lilly and Company | $48.45 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186644161 | CMS |
| Arcutis Biotherapeutics, Inc. | $2,850.00 | 01/22/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252343414 | CMS |
| Regeneron Healthcare Solutions, Inc. | $119.92 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213076826 | CMS |
| Galderma Laboratories, L.P. | $2,175.00 | 01/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234719554 | CMS |
| Blueprint Medicines Corporation | $800.00 | 01/16/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235812666 | CMS |
| Regeneron Pharmaceuticals, Inc. | $104.69 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213245047 | CMS |
| Novartis Pharmaceuticals Corporation | $6,400.00 | 01/02/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200450931 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $45,605.49 | 12 |
| PY2025 | Principal investigator | $498,325.11 | 28 |
| PY2024 | Recipient | $19,721.38 | 13 |
| PY2024 | Principal investigator | $158,525.44 | 43 |
| PY2023 | Recipient | $27,164.34 | 50 |
| PY2023 | Principal investigator | $667,845.30 | 77 |
| PY2022 | Recipient | $22,723.81 | 28 |
| PY2022 | Principal investigator | $769,822.80 | 20 |
| PY2021 | Recipient | $38,832.57 | 50 |
| PY2021 | Principal investigator | $260,905.37 | 26 |
| PY2020 | Recipient | $27,491.53 | 26 |
| PY2020 | Principal investigator | $159,909.87 | 19 |
| PY2019 | Recipient | $105,340.26 | 9 |
| PY2019 | Principal investigator | $131,541.40 | 35 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
40 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,639.00 | 12/22/2025 | Non-covered Recipient Entity Office Of Research Administration | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226107331 |
| Recipient | GENZYME CORPORATION | $1,250.00 | 12/02/2025 | Covered Recipient Physician | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | No dispute reported | 06/30/2026 | 1226120231 |
| Recipient | Novartis Pharmaceuticals Corporation | $25,335.54 | 11/05/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291288 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,135.00 | 11/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184124050 |
| Principal investigator 1 | GENZYME CORPORATION | $79,964.17 | 10/20/2025 | Non-covered Recipient Entity University Of Miami Umiami Medicine Dermatology | Severity of Atopic Dermatitis in skin of color: the Role of Type 2 Inflammation via Melanocytes, Fibromodulin, and Dendritic cells | No dispute reported | 06/30/2026 | 1226096306 |
| Recipient | GENZYME CORPORATION | $500.00 | 10/10/2025 | Covered Recipient Physician | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | No dispute reported | 06/30/2026 | 1226120235 |
| Recipient | GENZYME CORPORATION | $250.00 | 10/10/2025 | Covered Recipient Physician | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | No dispute reported | 06/30/2026 | 1226120238 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/17/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable | No dispute reported | 06/30/2026 | 1226120224 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/17/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable | No dispute reported | 06/30/2026 | 1226120227 |
| Principal investigator 1 | GENZYME CORPORATION | $79,964.17 | 09/08/2025 | Non-covered Recipient Entity University Of Miami Umiami Medicine Dermatology | Severity of Atopic Dermatitis in skin of color: the Role of Type 2 Inflammation via Melanocytes, Fibromodulin, and Dendritic cells | No dispute reported | 06/30/2026 | 1226096311 |
| Principal investigator 1 | GENZYME CORPORATION | $249,867.95 | 08/11/2025 | Non-covered Recipient Entity University Of Miami Office Of Research Administration Ora | ORIGINS: Cross Talk Between Melanocytes and Dendritic Cells Via OX40 Inducing an Increase in Inflammatory Skin Diseases of Skin of Color | No dispute reported | 06/30/2026 | 1226096438 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $523.78 | 08/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI HEALTH SYSTEM | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190313427 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,185.00 | 07/14/2025 | Non-covered Recipient Entity Office Of Research Administration | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226107225 |
| Recipient | PFIZER INC. | $3,200.00 | 07/11/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802974 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,178.61 | 07/07/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190292186 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $680.00 | 06/23/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210248 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $950.00 | 06/23/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210284 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,900.00 | 06/23/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210326 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 06/23/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210330 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 06/23/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210332 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,600.00 | 06/23/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210342 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,050.00 | 06/23/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210358 |
| Principal investigator 1 | Incyte Corporation | $5,440.00 | 06/05/2025 | Covered Recipient Teaching Hospital University Of Miami Hospital | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240480186 |
| Principal investigator 1 | Incyte Corporation | $5,450.00 | 06/05/2025 | Covered Recipient Teaching Hospital University Of Miami Hospital | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240480190 |
| Principal investigator 1 | Incyte Corporation | $9,295.00 | 06/05/2025 | Covered Recipient Teaching Hospital University Of Miami Hospital | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240480193 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 06/05/2025 | Covered Recipient Teaching Hospital University Of Miami Hospital | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240480198 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $335.40 | 05/22/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184197859 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $903.00 | 05/22/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184197861 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 05/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240608303 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 05/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240608306 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $335.40 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184190721 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $645.00 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184190723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,935.00 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184190725 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,024.00 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184190733 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 04/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240608301 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $2,600.70 | 04/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184124048 |
| Principal investigator 1 | Amgen Inc. | $965.24 | 03/25/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI HOSPITAL | A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies | No dispute reported | 06/30/2026 | 1246650452 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,398.00 | 03/14/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184173896 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,061.46 | 02/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184124046 |
| Recipient | Novartis Pharmaceuticals Corporation | $7,094.18 | 01/13/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190292191 |